RESUMO
Objective To observe the clinical efficacy of liraglutide combined with metformin in the treatment of newly diagnosed type2 diabetes mellitus (T2DM) accompanying non-alcoholic fatty liver disease (NAFLD).Methods 40 newly diagnosed patients with type 2 diabetes combined with fatty liver were randomly divided into observation group and control group.On the basis of lifestyle intervention,the observation group was given metformin 500 mg,oral,3 times/d,Liraglutide Injection 1.8 mg,subcutaneous injection,1 times/d,and the control group was given metformin 500 mg,orally,3 times/d.The treatment process lasted for 12 weeks.Waist circumference,body mass index (BMI),fasting plasma glucose (FPG),2 hour postprandial glucose (2 h PG),glycosylated hemoglobin A1 c (HbA1 c),alanine aminotransferase (ALT),aspartate transaminase (AST),glutamyl transpeptidase (GGT),total cholesterol (TC),triglyceride (TG),Transforming growth factor beta (TGF-β) and the degree of fatty liver were compared before and after treatment,and the adverse events were recorded.Results Compared with the control group,the degree of WC,BMI,FPG,2 h PG,HbA1c,TG,TGF-beta and fatty liver were significantly improved in the observation group (P ＜ 0.05).There was no significant difference in adverse reactions between the two groups (P ＞ 0.05).Conclusions Liraglutide combined with metformin is a new kind of safe and effective treatment for T2DM accompanying NAFLD.